The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease

Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease (KD), the most common cause of acquired heart disease in children, 10 –20% of patients are IVIG-resistant and require additional therapy. This group has an increased risk of coronary artery aneurysms (CAA) and there has been no adequately powered, randomized clinical trial in a multi-ethnic population to determine the optimal therapy for IVIG-resistant patients.

Source: Contemporary Clinical Trials - March 2, 2019 Category: Radiology Authors: Samantha C. Roberts, Sonia Jain, Adriana H. Tremoulet, Katherine K. Kim, Jane C. Burns, KIDCARE Multicenter Study Group, Vikram Anand, Marsha Anderson, Jocelyn Ang, Emily Ansusinha, Moshe Arditi, Negar Ashouri, Allison Bartlett, Archana Chatterjee, Robert Source Type: research